Testing a home-based model of care using misoprostol for prevention and treatment of postpartum hemorrhage: results from a randomized placebo-controlled trial conducted in Badakhshan province, Afghanistan

Table 2 PPH outcomes by study group*

	Misoprostol (800mcg SL) (n = 40)	Placebo (n = 39)	RR 95% CI	P value
Primary outcome
Hb drop ≥2 g/dL ^a	22 (56.4)	20 (60.6)	0.93 (0.61, 1.45)	0.45
Secondary outcomes
Post-delivery Hb (g/dL), mean ± SD ^b	10 ± 1.7	9.9 ± 1.7		0.94
Postpartum Hb ≤ 8 g/dL ^b	7 (17.5)	8 (21.1)	0.83 (0.29, 2.33)	0.78
Pre to post-delivery Hb drop (g/dL), mean ± SD ^a	2.4 ± 1.5	2.4 ± 1.8		0.99
Hb drop ≥3 g/dL ^a	13 (33.3)	12 (36.4)	0.92 (0.45, 1.89)	0.81
Transferred to facility from home	18 (45.0)	15 (38.5)	1.17 (0.66, 2.11)	0.56
Administered IV oxytocin at facility	17 (42.5)	14 (35.9)	1.18 (0.64, 2.21)	0.55
Other interventions (Ns listed):
Administered ergometrine	2	6
Manual removal of placenta	2	1
Suturing/tear repair	1	1
Hysterectomy/other surgery	0	0

Abbreviations: Hb hemoglobin, SL sublingual, RR relative risk, CI confidence interval
^* Data presented as n (%) unless otherwise stated
^a Pre and post Hb measures available for n = 39 in the misoprostol arm and n = 33 in the placebo arm
^b In one case (placebo) no post-delivery Hb was available for the one maternal death

ISSN: 1742-4755